B
Bull
Bull · 25%SILO
$0.73
情境價格
$2.460
-0.020 (-0.81%)收盤時
Loading chart…
- High
- 2.512
- Open
- 2.512
- VWAP
- 2.48
- Vol
- 7.82K
- Mkt Cap
- 3.58M
- Low
- 2.480
- Amount
- 19.43K
- EV/EBITDA, TTM
- 0.00
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
AI analysis of Silo Pharma Inc (SILO)
sellSilo Pharma Inc is not a good buy right now due to its extremely low RSI of 16.73, indicating it is oversold, and a significant year-to-date decline of 49.54%.
估值指標
The current forward P/E ratio for Silo Pharma Inc (SILO) is 0.00, compared to its 5-year average forward P/E of -1.41.
Alphio AI Price Scenarios for SILO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
8.508-19NASDAQ.COMSilo Pharma Secures Canadian Patent for SPC-15
8.508-10NASDAQ.COMSilo Pharma Secures European Patent for SPC-15
7.507-15NASDAQ.COMSilo Pharma's Subsidiary Joins AMD AI Developer Program
8.507-10seekingalphaSilo Pharma Secures $4 Million in Private Placement
- 9.006-29Newsfilter
Silo Pharma Initiates SPC-15 Robustness Study
SILO FAQ — answered by Alphio AI
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis. It operates in the Healthcare sector (APPAREL & OTHER FINISHD PRODS OF FABRICS & SIMILAR industry).
Silo Pharma Inc is not a good buy right now due to its extremely low RSI of 16.73, indicating it is oversold, and a significant year-to-date decline of 49.54%.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。